Product Information
ACARBOSE 25 MG TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.1798 per EA under NDC 00054014025. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 7, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054014025
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACARBOSEApproval Type
Generic (ANDA)
FDA Application
ANDA078470FDA Approved
5/7/2008
TE Code
AB
On Market Since
5/7/2008
Pharmacological Classes
Price Statistics
The NADAC for ACARBOSE 25 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 45.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1798 per EA |
|---|---|
| All-time high | $0.3772 (Jun 11, 2014) |
| All-time low | $0.1199 (Nov 20, 2024) |
| 52-week high | $0.1798 |
| 52-week low | $0.1409 |
| Median price | $0.1855 |
| Average price | $0.2116 |
| Largest weekly change | +37.8% (Oct 19, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acarbose market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Glucosidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACARBOSE 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ACARBOSE 25 MG TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $0.1798 per EA (NDC 00054014025), effective Sep 30, 2026.
How has the price of ACARBOSE 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for ACARBOSE 25 MG TABLET has declined 45.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ACARBOSE 25 MG TABLET?
Since Nov 28, 2013, the NADAC for ACARBOSE 25 MG TABLET has ranged from a low of $0.1199 (Nov 20, 2024) to a high of $0.3772 (Jun 11, 2014), with a median of $0.1855 per EA.
Are there cheaper alternatives to ACARBOSE 25 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ACARBOSE 25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ACARBOSE 25 MG TABLET?
ACARBOSE 25 MG TABLET (NDC 00054014025) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.